NS Medical Devices is using cookies
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
A strategic business segment within Rousselot® - the world-leading manufacturer of collagen-based solutions – Rousselot Biomedical has drawn upon 130 years of worldwide expertise and proven track record of pharmaceutical gelatins and collagens to develop innovative ranges of purified, modified and non-modified gelatins and collagens for biomedical applications.
With Rousselot X-Pure modified gelatins you can focus on what is truly important for you, achieving reproducible and consistent data. Watch our video to find out how we can help you get your research published faster.
Endotoxins can slow the pace of scientific progress for biomedical applications in tissue engineering and regenerative medicines.
Endotoxins are slowing the pace of scientific progress for biomedical applications in tissue engineering and regenerative medicines – here’s how.
SECTOR: Company Insight
A strategic business segment within Rousselot® - the world-leading manufacturer of collagen-based solutions – Rousselot Biomedical has drawn upon 130 years of worldwide expertise and proven track record of pharmaceutical gelatins and collagens to develop innovative ranges of purified, modified and non-modified gelatins and collagens for biomedical applications.
X-Pure®: A world-class range of customizable low-endotoxin gelatins and collagens for in vitro and in vivo applications
X-Pure® is a range of low-endotoxin, customizable, pharmaceutical-grade gelatins designed to ensure maximum quality and safety. The range comprises various gelatins and modified gelatins, namely X-Pure, X-Pure GelMA, and X-Pure GelDAT. Notably X-Pure GelMA is the world’s first gelatin methacryloyl produced under GMP conditions.
The ultra-purified and modified gelatins within the X-Pure range find application in diverse fields such as regenerative medicine, drug delivery, embolization, and hemostasis projects.
New Quali-Pure® range of pharmaceutical gelatins
Specifically designed to support biomedical application areas including embolization, wound healing, drug delivery, vaccines and hemostatics, Quali-Pure® delivers biocompatibility, biodegradability, controlled endotoxin levels, and batch-to-batch consistency.
All Rousselot biomedical gelatins are GMP* ready and fully documented to support medical device compliance with ISO standards and the new EU Medical Device Regulation (MDR).
Rousselot’s research and GMP grades are functionally equivalent, streamlining the transition from research to clinical trials by minimizing the necessity for data revalidation.
Rousselot Biomedical is committed to engineering, accelerating and scaling superior products to help transform ideas into biomedical solutions worldwide, using our scientific expertise and collaborative approach to support end-to-end partnerships and to “Improve patients’ lives”.
* IPEC & PQG Joint Good Manufacturing Practices Guide for Pharmaceutical Excipients
Rousselot BV
Kanaaldijk Noord 20
5691 NM SON
The Netherlands
Phone: +31 499 364100
For more information please visit: www.rousselot.com/biomedical
X-Pure® is a range of premium-grade gelatins, with tunable functionalities in addition to high-purity ≤10EU/g. X-Pure gelatins are optimized for in-vivo or in-vitro research and clinical applications and produced under GMP conditions. They can be designed or customized to provide significant technical advantages for the development of biomedical applications.
Due to its excellent biocompatibility, biodegradability, and tunability, Gelatin methacryloyl (GelMA) is probably the most popular biomaterial used in 3D bioprinting, tissue engineering and 3D cell culture applications.
X-Pure® GelDAT is the world’s first purified Gelatin Desaminotyrosine. X-Pure GelDAT hydrogels are ideal for research and preclinical development in regenerative medicine, drug release and complex wound dressings due to their ability to crosslink with tissues and their purity.
Quali-Pure® is a range of pharmaceutical gelatins, that has been specifically designed to support biomedical application areas including embolization, wound healing, drug delivery, vaccines and hemostatics.
3D bioprinting is a very popular tissue engineering technology used in the field of regenerative medicine. However, to create successful tissue constructs, it is of critical importance to select suitable biomaterials. In this whitepaper, we explore the benefits of using gelatin as a bioink in various 3D bioprinting technologies, and describe how the low endotoxin gelatins in the X-Pure® assortment – a range of highly purified gelatins – can help secure proper cellular characteristics and functionalities, and enable (bio) medical applications with low immunogenicity.
Download White PaperCan ultra-pure GMP grade gelatins help support faster and simpler development of parenteral formulations, including vaccines? As a biomaterial of choice, pharmaceutical gelatin is widely recognized for its use in parenteral applications. Highly biocompatible, purified gelatin helps provide drug protection, offers superior drug loading rates, and great flexibility in the control of drug release. It helps stabilize vaccines and other formulations and minimizes side reactions while ensuring patient safety. These are just few examples of the many benefits provided by purified gelatins. This white paper explores these various advantages and describes how X-Pure® extra purified GMP quality gelatins can help realize superior parenteral formulations.
Download White PaperGelatin-based micro- and submicron particles have gained increased interest in the fields of drug delivery and regenerative medicine. However, these micro- and submicron particle formulations can contain endotoxins, which is a safety challenge in these specific applications. A new and ultra-pure gelatin, X-Pure, is now available for preparing gelatin micro- and submicron particles with exceptionally low endotoxin levels. This white paper provides background information on gelatin-based micro- and submicron particles properties and application examples.
Download White PaperThis whitepaper outlines the benefits of gelatin and collagen for (bio)medical applications and highlights the importance of low endotoxin levels for optimal API (Active Pharmaceutical Ingredients) delivery and (bio)medical engineering materials. The paper also highlights the value-added expertise that Rousselot can offer to researchers, developpers and manufacturers of (bio)medical applications of gelatin, hydrolyzed gelatin and collagen.
Download White PaperDarling Ingredients’ health brand Rousselot, a global leader in gelatin- and collagen-based solutions, announced today that its high-quality, research- and technical-grade gelatins are now available for online purchase in Canada, Europe, South Korea and the U.S. through BIO INX, a pioneering developer and distributor of materials for 3D bioprinting.
Irving, United States, 15th March 2023 / Sciad Newswire / Darling Ingredients’ health brand Rousselot, the global leader1 in collagen-based solutions, announced today that a new study has found that utilization of highly purified gelatin biomaterials for 3D in vitro models can significantly enhance the reliability and reproducibility in these models, creating new possibilities for replacing preclinical animal trials.
Irving, United States, 16th November 2022 / Sciad Newswire / Darling Ingredients’ Health Brand, Rousselot, the global leader in collagen-based solutions, and Gelomics, the world-leading provider of fully integrated 3D cell, organoid and tissue culture technologies, have entered into a cobranding partnership. Rousselot Biomedical will supply Gelomics with its X-Pure GelMA (gelatin methacryloyl), a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel™ 3D Tissue Culture System.
Irving, United States, May 4 2022 / Sciad Newswire / Rousselot®, Darling Ingredients’ health brand and the global leader of collagen-based solutions1, launches Quali-Pure™ HGP 2000, a new endotoxin-controlled, pharmaceutical-grade gelatin specifically designed for vaccines and wound healing applications. As the latest addition to Rousselot Biomedical’s rapidly expanding product offering, this new non-gelling hydrolyzed gelatin further extends the scope of biomedical applications covered by Rousselot products.
Irving, United States, 13th April 2022 / Sciad Newswire / Rousselot®, Darling Ingredients’ health brand, and the global leader of collagen-based solutions1 announces the launch of GMP grade GelMA. X-Pure® GelMA is the first gelatin methacryloyl, or GelMA, on the market to be produced under GMP conditions2.
